Loading
NASDAQHealthcareBiotechnology
Latest quote
$7.56
+$0.05 · +0.67%
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Regular session
$7.56
+$0.05 · +0.67%
Regular session · ET · Market data may be delayed.
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Day range
Current $7.56
52-week range
Current $7.56
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
34
Expensive
Sentiment
68
Bullish
Risk
58
Elevated Risk
Momentum
48
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Day range
Current $7.56
52-week range
Current $7.56
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 51.82M USD | 63.72M USD | 58.44M USD | 51.49M USD | 43.52M USD |
| Cost of goods sold | 6.57M USD | 5.63M USD | 5.28M USD | 4.54M USD | 4.41M USD |
| Gross profit | 45.25M USD | 58.1M USD | 53.16M USD | 46.95M USD | 39.12M USD |
| Research and development | 197.1M USD | 127.64M USD | 61.06M USD | 53.46M USD | 50.08M USD |
| Selling, general, and administrative | 118.3M USD | 102.24M USD | 74.49M USD | 72.15M USD | 67.07M USD |
| Operating expenses | 315.39M USD | 229.88M USD | 135.54M USD | 125.61M USD | 117.15M USD |
| Interest income | 18.36M USD | 20.28M USD | 3.98M USD | 798K USD | 33K USD |
| Interest expense | 11.84M USD | 13.58M USD | 11.34M USD | 7.02M USD | 6.67M USD |
| Depreciation and amortization | 4.32M USD | 3.79M USD | 2.98M USD | 2.11M USD | 2.42M USD |
| Operating income | −270.02M USD | −171.78M USD | −82.38M USD | −78.65M USD | −78.04M USD |
| Net income | −265.94M USD | −193.51M USD | −80.74M USD | −71.04M USD | −6.55M USD |
Company facts updated Oct 9, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI69.62M0.00%2.3T USD0.03%$380.81+0.33%
iShares Russell 2000 ETFIWM42.48M0.05%77.7B USD0.19%$278.19+0.22%
Vanguard Extended Market ETFVXF21.39M0.02%95.4B USD0.05%$234.05+0.39%
Vanguard Russell 2000 ETFVTWO12.42M0.07%18B USD0.06%$112.36+0.23%
iShares Russell 2000 Growth ETFIWO12.36M0.09%14.04B USD0.24%$355.19+0.49%
Invesco Pharmaceuticals ETFPJP11.75M2.16%543.56M USD0.58%$121.61+0.51%
Dimensional - US Small Cap ETFDFAS8.99M0.03%33.66B USD0.31%$78.19+0.12%
Schwab U.S. Small-Cap ETFSCHA7.04M0.03%21.7B USD0.03%$32.725+0.20%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOInvesco Pharmaceuticals ETFPJPDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
